Herpes simplex virus and human papillomavirus genital infections: new and investigational therapeutic options.
Human papillomavirus and Herpes simplex virus are the most common genital viral infections encountered in clinical practice worldwide. We reviewed the literature focusing on new and experimental treatment modalities for both conditions, based on to the evidence-based data available. The modalities evaluated include topical agents such as immune response modifiers (imiquimod, resiquimod, and interferon), antivirals (penciclovir, cidofovir, and foscarnet), sinecatechins, microbiocidals (SPL7013 gel, and PRO 2000 gel), along with experimental (oligodeoxynucleotides), immunoprophylactic, and immunotherapeutic vaccines.
Viera
Martha H
MH
Department of Dermatology and Cutaneous Surgery, Miller School of Medicine, University of Miami, Miami, FL 33136, USA. dermatology.research@med.miami.edu
Amini
Sadegh
S
Huo
Ran
R
Konda
Sailesh
S
Block
Samantha
S
Berman
Brian
B
D000998:Antiviral Agents / Q000627:therapeutic use*; D003218:Condylomata Acuminata / Q000188:drug therapy* / Q000276:immunology; D015195:Drug Design; D006558:Herpes Genitalis / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D030361:Papillomavirus Infections / Q000188:drug therapy* / Q000276:immunology
D000998:Antiviral Agents